FDG-PET for clinical use

[1]  M. Bamberg,et al.  Metaanalyse zum Stellenwert der Positronen-Emissions-Tomographie mit F-18-Fluorodesoxyglukose (FDG-PET) bei Lungentumoren1 - Diskussionsbasis der deutschen Konsensus-Konferenz Onko-PET 2000 - , 2001 .

[2]  S S Gambhir,et al.  A tabulated summary of the FDG PET literature. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[3]  M. Schwaiger,et al.  Neoadjuvant Therapy of Esophageal Squamous Cell Carcinoma: Response Evaluation by Positron Emission Tomography , 2001, Annals of surgery.

[4]  G Noël,et al.  [Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomised trials]. , 2001, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.

[5]  A. Tosteson,et al.  Mammography in 53,803 women from the New Hampshire mammography network. , 2000, Radiology.

[6]  L. Mortelmans,et al.  Histopathologic Validation of Lymph Node Staging With FDG-PET Scan in Cancer of the Esophagus and Gastroesophageal Junction: A Prospective Study Based on Primary Surgery With Extensive Lymphadenectomy , 2000, Annals of surgery.

[7]  M. Schwaiger,et al.  Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  P. Dupont,et al.  Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  M E Phelps,et al.  Positron emission tomography provides molecular imaging of biological processes. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[10]  O. Schober,et al.  FDG-PET for detection of osseous metastases from malignant primary bone tumours: comparison with bone scintigraphy , 2000, European Journal of Nuclear Medicine.

[11]  J A Werner,et al.  FDG PET detection of unknown primary tumors. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[12]  J. Nährig,et al.  Positron emission tomography using [(18)F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  P F Sharp,et al.  Positron emission tomography using [(18)F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Peter C Gøtzsche,et al.  Is screening for breast cancer with mammography justifiable? , 2000, The Lancet.

[15]  Lotty Hooft,et al.  How to perform a comprehensive search for FDG-PET literature , 2000, European Journal of Nuclear Medicine.

[16]  J. Nährig,et al.  Positron emission tomography using [(18)F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  W. Arnold,et al.  Ist die Positronen-Emissions-Tomographie (PET) zum Nachweis tumorbefallener Halslymphknoten bei Plattenepithelkarzinomen des Kopf-Halsbereiches in der klinischen Routine sinnvoll einsetzbar? , 2000, Oto-Rhino-Laryngologia Nova.

[18]  O. Schober,et al.  Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicentre study , 1999, European Journal of Nuclear Medicine.

[19]  M. Schwaiger,et al.  Lymph node detection of head and neck squamous cell carcinomas by positron emission tomography with fluorodeoxyglucose F 18 in a routine clinical setting. , 1999, Archives of otolaryngology--head & neck surgery.

[20]  B Ghaye,et al.  Value of FDG-PET in detecting residual or recurrent nonsmall cell lung cancer. , 1999, The European respiratory journal.

[21]  R L Wahl,et al.  Metastases from non-small cell lung cancer: mediastinal staging in the 1990s--meta-analytic comparison of PET and CT. , 1999, Radiology.

[22]  A. Ezzat,et al.  Positron emission tomography in breast cancer: a clinicopathological correlation of results. , 1999, The British journal of radiology.

[23]  F. Fazio,et al.  FDG/PET and spiral CT image fusion for medistinal lymph node assessment of non-small cell lung cancer patients. , 1999, The Journal of cardiovascular surgery.

[24]  S. Reske,et al.  Evaluation of neoadjuvant therapy response of osteogenic sarcoma using FDG PET. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[25]  B. Thompson,et al.  PET, CT, and MRI with Combidex for mediastinal staging in non-small cell lung carcinoma. , 1999, The Annals of thoracic surgery.

[26]  V. Lowe,et al.  Primary and recurrent early stage laryngeal cancer: preliminary results of 2-[fluorine 18]fluoro-2-deoxy-D-glucose PET imaging. , 1999, Radiology.

[27]  S. Berlangieri,et al.  F-18 fluorodeoxyglucose positron emission tomography in the non-invasive staging of non-small cell lung cancer. , 1999, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[28]  S. Reske,et al.  FDG PET can replace bone scintigraphy in primary staging of malignant lymphoma. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[29]  P C Goodman,et al.  Staging non-small cell lung cancer with whole-body PET. , 1999, Radiology.

[30]  D. Noh,et al.  Detection of cancer in augmented breasts by positron emission tomography. , 1999, The European journal of surgery = Acta chirurgica.

[31]  H. Heimpel,et al.  Role of whole body FDG-PET imaging in predicting relapse of malignant lymphoma in patients with residual masses after treatment , 1999 .

[32]  G. Jerusalem,et al.  Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. , 1999, Blood.

[33]  N. Sadato,et al.  FDG PET to evaluate combined intra-arterial chemotherapy and radiotherapy of head and neck neoplasms. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[34]  L. Friberg,et al.  18F-FDG whole body positron emission tomography (PET) in patients with unknown primary tumours (UPT). , 1999, European journal of cancer.

[35]  Tomio Inoue,et al.  FDG-PET in differential diagnosis and grading of chondrosarcomas. , 1999, Journal of computer assisted tomography.

[36]  I. Francis,et al.  Pheochromocytomas: imaging with 2-[fluorine-18]fluoro-2-deoxy-D-glucose PET. , 1999, Radiology.

[37]  R L Wahl,et al.  Head and neck cancer: detection of recurrence with three-dimensional principal components analysis at dynamic FDG PET. , 1999, Radiology.

[38]  W. Hepburn,et al.  14 years of follow-up from the Edinburgh randomised trial of breast-cancer screening , 1999, The Lancet.

[39]  K Schnabel,et al.  18F-deoxyglucose positron emission tomography (FDG-PET) for the planning of radiotherapy in lung cancer: high impact in patients with atelectasis. , 1999, International journal of radiation oncology, biology, physics.

[40]  A. Alavi,et al.  Detection of recurrent head and neck squamous cell carcinomas after radiation therapy with 2‐18f‐fluoro‐2‐deoxy‐D‐glucose positron emission tomography , 1999, The Laryngoscope.

[41]  D. Lee,et al.  Value of FDG PET in papillary thyroid carcinoma with negative 131I whole-body scan. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[42]  M. Hanasono,et al.  Uses and limitations of fdg positron emission tomography in patients with head and neck cancer , 1999, The Laryngoscope.

[43]  S. Reske,et al.  Fluorodeoxyglucose positron emission tomography of soft tissue tumours: is a non-invasive determination of biological activity possible? , 1999, European Journal of Nuclear Medicine.

[44]  W. Chapman,et al.  18Fluorodeoxyglucose-positron emission tomography in the management of patients with suspected pancreatic cancer. , 1999, Annals of surgery.

[45]  P. Valk,et al.  Whole-body PET imaging with [18F]fluorodeoxyglucose in management of recurrent colorectal cancer. , 1999, Archives of surgery.

[46]  J. J. Coleman,et al.  Prospective study of fluorodeoxyglucose-positron emission tomography imaging of lymph node basins in melanoma patients undergoing sentinel node biopsy. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  P. Marsden,et al.  Prospective evaluation of soft tissue masses and sarcomas using fluorodeoxyglucose positron emission tomography , 1999, The British journal of surgery.

[48]  M. Tatsumi,et al.  Feasibility of fluorodeoxyglucose dual-head gamma camera coincidence imaging in the evaluation of lung cancer: comparison with FDG PET. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[49]  G. Murray,et al.  Positron emission tomographic imaging with fluorodeoxyglucose isefficacious in evaluating malignant pulmonary disease. , 1999, The Journal of thoracic and cardiovascular surgery.

[50]  M. Zimny,et al.  The role of 18F-fluoro-deoxyglucose positron emission tomography (18F-FDG PET) in diagnosis of ovarian cancer. , 1999, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

[51]  M. O'Doherty,et al.  Evaluation of fluorine-18-fluorodeoxyglucose whole body positron emission tomography imaging in the staging of lung cancer. , 1999, The Annals of thoracic surgery.

[52]  P. Dupont,et al.  Additional value of whole-body positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose in recurrent colorectal cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  J. Albes,et al.  Improvement of non-small-cell lung cancer staging by means of positron emission tomography. , 1999, The Thoracic and cardiovascular surgeon.

[54]  G. Graeber,et al.  Comparative efficacy of positron emission tomography with FDG and computed tomographic scanning in preoperative staging of non-small cell lung cancer. , 1999, Annals of surgery.

[55]  S. Reske,et al.  Detection of liver metastases from pancreatic cancer using FDG PET. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[56]  H. Brambs,et al.  Präoperative Dignitätsbeurteilung asymptomatischer Adnextumoren mittels Positronen-Emissions-Tomographie und F-18-FluordeoxygIukose , 1999, Nuklearmedizin.

[57]  J. Neuerburg,et al.  Klinische Wertigkeit der FDG-PET zur Therapiekontrolle bei malignen Lymphomen – Ergebnisse einer retrospektiven Studie an 72 Patienten , 1999, Nuklearmedizin.

[58]  M. Singer,et al.  Metastatic head and neck cancer: role and usefulness of FDG PET in locating occult primary tumors. , 1999, Radiology.

[59]  J. Eary,et al.  Positron Emission Tomography in Grading Soft Tissue Sarcomas. , 1999, Seminars in musculoskeletal radiology.

[60]  Michael J. Welch,et al.  Positron emission tomographic assessment of ”metabolic flare” to predict response of metastatic breast cancer to antiestrogen therapy , 1999, European Journal of Nuclear Medicine.

[61]  P. Marsden,et al.  A PET study of 18FDG uptake in soft tissue masses , 1999, European Journal of Nuclear Medicine.

[62]  R. Coleman,et al.  Diagnosis of pancreatic carcinoma: role of FDG PET. , 1998, AJR. American journal of roentgenology.

[63]  E. Silberstein.  Prevalence of adverse reactions to positron emitting radiopharmaceuticals in nuclear medicine. Pharmacopeia Committee of the Society of Nuclear Medicine. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[64]  W. Heiss,et al.  [Clinical value of positron emission tomography in neuromedicine. Position paper on results of an interdisciplinary consensus conference]. , 1998, Der Nervenarzt.

[65]  D. Rubello,et al.  [Positron emission tomography (PET) with 18-fluorodeoxyglucose (FDG) in the diagnosis and preoperative staging of head and neck tumors: a prospective study]. , 1998, Acta otorhinolaryngologica Italica : organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale.

[66]  M. Schwaiger,et al.  Controlled prospective study of positron emission tomography using the glucose analogue [18F]fluorodeoxyglucose in the evaluation of pulmonary nodules , 1998, The British journal of surgery.

[67]  V. Lowe,et al.  F-18 FDG PET scan after radiotherapy for early-stage larynx cancer. , 1998, Clinical nuclear medicine.

[68]  F. Jamar,et al.  Can dual-headed 18F-FDG SPET imaging reliably supersede PET in clinical oncology? A comparative study in lung and gastrointestinal tract cancer. , 1998, Nuclear medicine communications.

[69]  T. Yen,et al.  Detection of recurrent or persistent nasopharyngeal carcinomas after radiotherapy with 18-fluoro-2-deoxyglucose positron emission tomography and comparison with computed tomography. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[70]  P. Dupont,et al.  Potential use of FDG-PET scan after induction chemotherapy in surgically staged IIIa-N2 non-small-cell lung cancer: a prospective pilot study. The Leuven Lung Cancer Group. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[71]  J Kotzerke,et al.  Whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin's disease. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[72]  R. Rubens,et al.  Detection of bone metastases in breast cancer by 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[73]  M. Greco,et al.  Association between [18F]fluorodeoxyglucose uptake and postoperative histopathology, hormone receptor status, thymidine labelling index and p53 in primary breast cancer: a preliminary observation , 1998, European Journal of Nuclear Medicine.

[74]  G. V. von Schulthess,et al.  Detection of extrathoracic metastases by positron emission tomography in lung cancer. , 1998, The Annals of thoracic surgery.

[75]  U. Pastorino,et al.  Selective use of PET scan in the preoperative staging of NSCLC. , 1998, Lung cancer.

[76]  G. Hör,et al.  Prospective comparison of 18F-FDG PET with conventional imaging modalities (CT, MRI, US) in lymph node staging of head and neck cancer , 1998, European Journal of Nuclear Medicine.

[77]  P. Sharp,et al.  Staging of the axilla in breast cancer: accurate in vivo assessment using positron emission tomography with 2-(fluorine-18)-fluoro-2-deoxy-D-glucose. , 1998, Annals of surgery.

[78]  R. Gupta,et al.  Positron emission tomography plus serum TA90 immune complex assay for detection of occult metastatic melanoma. , 1998, Journal of the American College of Surgeons.

[79]  M. Singer,et al.  Clinical utility of positron emission tomography with 18F-fluorodeoxyglucose in detecting residual/recurrent squamous cell carcinoma of the head and neck. , 1998, AJNR. American journal of neuroradiology.

[80]  W. Vaalburg,et al.  Positron emission tomography for staging of oesophageal and gastroesophageal malignancy. , 1998, British Journal of Cancer.

[81]  M. Bergström,et al.  Positron emission tomography with 5-hydroxytryprophan in neuroendocrine tumors. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[82]  M Schwaiger,et al.  Positron emission tomography in non-Hodgkin's lymphoma: assessment of chemotherapy with fluorodeoxyglucose. , 1998, Blood.

[83]  J Bogaert,et al.  Lymph node staging in non-small-cell lung cancer with FDG-PET scan: a prospective study on 690 lymph node stations from 68 patients. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[84]  H. Yagata,et al.  Predicting the prognoses of breast carcinoma patients with positron emission tomography using 2‐deoxy‐2‐fluoro[18F]‐D‐glucose , 1998, Cancer.

[85]  G. Glatting,et al.  FDG PET: elevated plasma glucose reduces both uptake and detection rate of pancreatic malignancies. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[86]  Michael O'Doherty,et al.  Evaluation of fluorodeoxyglucose positron emission tomography in the management of soft-tissue sarcomas , 1998 .

[87]  G. Hör,et al.  Primary staging and follow‐up of high risk melanoma patients with whole‐body 18F‐fluorodeoxyglucose positron emission tomography , 1998, Cancer.

[88]  W. Holder,et al.  Effectiveness of positron emission tomography for the detection of melanoma metastases. , 1998, Annals of surgery.

[89]  M. A. Smith,et al.  Evaluation of fluorodeoxyglucose positron emission tomography in the management of soft-tissue sarcomas. , 1998, The Journal of bone and joint surgery. British volume.

[90]  J. D. van der Walt,et al.  Detection of lymphoma in bone marrow by whole-body positron emission tomography. , 1998, Blood.

[91]  D. Mankoff,et al.  Quantitative [F-18]fluorodeoxyglucose positron emission tomography in pretreatment and grading of sarcoma. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[92]  M P Sandler,et al.  Evaluation of benign vs malignant hepatic lesions with positron emission tomography. , 1998, Archives of surgery.

[93]  K. Greven,et al.  Laryngeal Radionecrosis versus Recurrent Cancer: A Clinical Approach , 1998, The Annals of otology, rhinology, and laryngology.

[94]  J. Roodenburg,et al.  Detection of unknown occult primary tumors using positron emission tomography , 1998, Cancer.

[95]  D Delbeke,et al.  Prospective investigation of positron emission tomography in lung nodules. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[96]  S U Berlangieri,et al.  The contribution of 18F-fluoro-2-deoxy-glucose positron emission tomographic imaging to radiotherapy planning in lung cancer. , 1998, Lung cancer.

[97]  H. Abdel-Nabi,et al.  Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET: correlation with histopathologic and CT findings. , 1998, Radiology.

[98]  M. Phelps,et al.  Accuracy of whole-body fluorine-18-FDG PET for the detection of recurrent or metastatic breast carcinoma. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[99]  D. Noh,et al.  Diagnostic Value of Positron Emission Tomography for Detecting Breast Cancer , 1998, World Journal of Surgery.

[100]  E. Merkle,et al.  Extranodal malignant lymphoma: detection with FDG PET versus CT. , 1998, Radiology.

[101]  S. Reske,et al.  18-F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[102]  D. Mankoff,et al.  Tumor metabolic rates in sarcoma using FDG PET. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[103]  H. Tonami,et al.  Comparison of fluorine-18-FDG PET and thallium-201 SPECT in evaluation of lung cancer. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[104]  S. Manolidis,et al.  The use of positron emission tomography scanning in occult and recurrent head and neck cancer. , 1998, Acta oto-laryngologica. Supplementum.

[105]  M. Greco,et al.  Prospective evaluation of fluorine-18-FDG PET in presurgical staging of the axilla in breast cancer. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[106]  V. Lowe,et al.  Evaluation of chemotherapy response in patients with advanced head and neck cancer using [F‐18]fluorodeoxyglucose positron emission tomography , 1997, Head & neck.

[107]  P. Chieng,et al.  18F-2-fluoro-2-deoxy-D-glucose positron emission tomography of head and neck in patients with nasopharyngeal carcinomas. , 1997, Oncology reports.

[108]  R. Hustinx,et al.  Whole-body 18FDG positron emission tomography in the staging of non-small cell lung cancer. , 1997, The European respiratory journal.

[109]  M. Dietlein,et al.  Fluorine-18 fluorodeoxyglucose positron emission tomography and iodine-131 whole-body scintigraphy in the follow-up of differentiated thyroid cancer , 1997, European Journal of Nuclear Medicine.

[110]  G. Patterson,et al.  Improvement in staging of esophageal cancer with the addition of positron emission tomography. , 1997, The Annals of thoracic surgery.

[111]  W. Chapman,et al.  Staging recurrent metastatic colorectal carcinoma with PET. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[112]  N. Dewan,et al.  Likelihood of malignancy in a solitary pulmonary nodule: comparison of Bayesian analysis and results of FDG-PET scan. , 1997, Chest.

[113]  M Schwaiger,et al.  Breast imaging with fluorine-18-FDG PET: quantitative image analysis. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[114]  M. Pompili,et al.  Characterization of pulmonary nodules and mediastinal staging of bronchogenic carcinoma with F-18 fluorodeoxyglucose positron emission tomography. , 1997, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[115]  J Kotzerke,et al.  Lymphoma: role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging. , 1997, Radiology.

[116]  J. Ruhlmann,et al.  Value of 18fluoro-deoxyglucose positron emission tomography in the staging of recurrent breast carcinoma. , 1997, Anticancer research.

[117]  L. Adler,et al.  Axillary lymph node metastases: screening with [F-18]2-deoxy-2-fluoro-D-glucose (FDG) PET. , 1997, Radiology.

[118]  R. Coleman,et al.  Evaluation of adrenal masses in patients with bronchogenic carcinoma using 18F-fluorodeoxyglucose positron emission tomography. , 1997, AJR. American journal of roentgenology.

[119]  S. Reske,et al.  Lymph node staging in non-small cell lung cancer: evaluation by [18F]FDG positron emission tomography (PET). , 1997, Thorax.

[120]  J. Roodenburg,et al.  Detection of unknown primary head and neck tumors by positron emission tomography. , 1997, International journal of oral and maxillofacial surgery.

[121]  A. Bogni,et al.  The Contribution of Positron Emission Tomography (Pet) with 18F-Fluorodeoxyglucose (Fdg) in the Preoperative Detection of Axillary Metastases of Breast Cancer: The Experience of the National Cancer Institute of Milan , 1997, Tumori.

[122]  Benjamin Djulbegovic,et al.  Decision Making in Oncology: Evidence-Based Management , 1997 .

[123]  F Dehdashti,et al.  Staging of esophageal cancer with 18F-fluorodeoxyglucose positron emission tomography. , 1997, AJR. American journal of roentgenology.

[124]  G. V. von Schulthess,et al.  Non-small cell lung cancer: nodal staging with FDG PET versus CT with correlative lymph node mapping and sampling. , 1997, Radiology.

[125]  R. Coleman,et al.  Pulmonary abnormalities and PET data analysis: a retrospective study. , 1997, Radiology.

[126]  F. Jänicke,et al.  Metabolische Charakterisierung von Ovarialtumoren mit der Positronen-Emissions-Tomographie und F-18-Fluordeoxyglukose , 1997 .

[127]  A. Sundin,et al.  [18F] FDG PET in gastric non-Hodgkin's lymphoma. , 1997, Acta oncologica.

[128]  K. Erlandsson,et al.  Early prediction of treatment outcome in head and neck cancer with 2-18FDG PET. , 1997, Acta oncologica.

[129]  L. Radulescu,et al.  [Cervical lymph node metastases of unknown origin]. , 1997, Revista medico-chirurgicala a Societatii de Medici si Naturalisti din Iasi.

[130]  M Schwaiger,et al.  Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(fluorine-18)-fluoro-2-deoxy-D-glucose. , 1996, Journal of the National Cancer Institute.

[131]  E. Gunel,et al.  Probability of malignancy in solitary pulmonary nodules using fluorine-18-FDG and PET. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[132]  David J. Yang,et al.  Evaluation of preoperative chemotherapy using PET with fluorine-18-fluorodeoxyglucose in breast cancer. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[133]  M. Sasaki,et al.  A clinical evaluation of FDG-PET to assess the response in radiation therapy for bronchogenic carcinoma , 1996, Annals of nuclear medicine.

[134]  D. Delbeke,et al.  Evaluation of pulmonary lesions with FDG-PET. Comparison of findings in patients with and without a history of prior malignancy. , 1996, Chest.

[135]  J. Sunderland,et al.  Mediastinal lymph node staging of non-small-cell lung cancer: a prospective comparison of computed tomography and positron emission tomography. , 1996, The Journal of thoracic and cardiovascular surgery.

[136]  A. Dowlati,et al.  Evaluation of the solitary pulmonary nodule by positron emission tomography imaging. , 1996, The European respiratory journal.

[137]  M. Maisey,et al.  FDG‐PET screening for cerebral metastases in patients with suspected malignancy , 1996, Nuclear medicine communications.

[138]  M. Mandelkern,et al.  Fluorodeoxyglucose-positron emission tomography in the detection and staging of lung cancer. , 1996, American journal of respiratory and critical care medicine.

[139]  P. Valk,et al.  Staging non-small cell lung cancer by whole-body positron emission tomographic imaging. , 1995, The Annals of thoracic surgery.

[140]  V. Lowe,et al.  Thoracic nodal staging with PET imaging with 18FDG in patients with bronchogenic carcinoma. , 1995, Chest.

[141]  J. Reed,et al.  Mediastinal staging of non-small-cell lung cancer with positron emission tomography. , 1995, American journal of respiratory and critical care medicine.

[142]  V J Lowe,et al.  Lung tumor growth correlates with glucose metabolism measured by fluoride-18 fluorodeoxyglucose positron emission tomography. , 1995, The Annals of thoracic surgery.

[143]  H. Minn,et al.  Increased glucose metabolism in untreated non-Hodgkin's lymphoma: a study with positron emission tomography and fluorine-18-fluorodeoxyglucose. , 1995, Blood.

[144]  J. Bishop,et al.  Decision logic for retreatment of asymptomatic lung cancer recurrence based on positron emission tomography findings. , 1995, International journal of radiation oncology, biology, physics.

[145]  V J Lowe,et al.  Detection of primary and recurrent lung cancer by means of F-18 fluorodeoxyglucose positron emission tomography (FDG PET). , 1995, The Journal of thoracic and cardiovascular surgery.

[146]  A. Buck,et al.  Malignant melanoma: staging with whole-body positron emission tomography and 2-[F-18]-fluoro-2-deoxy-D-glucose. , 1995, Radiology.

[147]  J. Bergh,et al.  Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: a method for early therapy evaluation? , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[148]  David J. Yang,et al.  Detecting recurrent or residual lung cancer with FDG-PET. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[149]  Richard P. Lewis,et al.  Guidelines for clinical use of cardiac radionuclide imaging. Report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Committee on Radionuclide Imaging), developed in collaboration with the American Soci , 1995, Journal of the American College of Cardiology.

[150]  M. Goldberg,et al.  Indeterminate adrenal mass in patients with cancer: evaluation at PET with 2-[F-18]-fluoro-2-deoxy-D-glucose. , 1995, Radiology.

[151]  G. Rassner,et al.  Positron emission tomography and ultrasonography. A comparative retrospective study assessing the diagnostic validity in lymph node metastases of malignant melanoma. , 1995, Archives of dermatology.

[152]  J M Hoffman,et al.  Semiquantitative and visual analysis of FDG-PET images in pulmonary abnormalities. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[153]  R. Wahl,et al.  Staging of mediastinal non-small cell lung cancer with FDG PET, CT, and fusion images: preliminary prospective evaluation. , 1994, Radiology.

[154]  V. Lowe,et al.  Persistent or recurrent bronchogenic carcinoma: detection with PET and 2-[F-18]-2-deoxy-D-glucose. , 1994, Radiology.

[155]  N. Gupta,et al.  Positron emission tomography of lung tumors and mediastinal lymph nodes using [18F]fluorodeoxyglucose. The Members of the PET-Lung Tumor Study Group. , 1994, The Annals of thoracic surgery.

[156]  R L Wahl,et al.  Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[157]  M P Frick,et al.  Diagnostic efficacy of PET-FDG imaging in solitary pulmonary nodules. Potential role in evaluation and management. , 1993, Chest.

[158]  Michael E. Phelps,et al.  Cancer Detection with Whole‐Body PET Using 2‐[18F]Fluoro‐2-Deoxy‐D-Glucose , 1993, Journal of computer assisted tomography.

[159]  G. Hortobagyi,et al.  Positron emission tomography with fluorine‐18‐deoxyglucose in the detection and staging of breast cancer , 1993, Cancer.

[160]  J L Sunshine,et al.  Evaluation of breast masses and axillary lymph nodes with [F-18] 2-deoxy-2-fluoro-D-glucose PET. , 1993, Radiology.

[161]  M. J. Fusselman,et al.  Brain metastases from non-central nervous system tumors: evaluation with PET. , 1993, Radiology.

[162]  M E Phelps,et al.  The application of positron emission tomographic imaging with fluorodeoxyglucose to the evaluation of breast disease. , 1992, Annals of surgery.

[163]  D L Kent,et al.  Disease, level of impact, and quality of research methods. Three dimensions of clinical efficacy assessment applied to magnetic resonance imaging. , 1992, Investigative radiology.

[164]  R L Wahl,et al.  Primary and metastatic breast carcinoma: initial clinical evaluation with PET with the radiolabeled glucose analogue 2-[F-18]-fluoro-2-deoxy-D-glucose. , 1991, Radiology.

[165]  L. Sachs,et al.  Statistische Methoden : planung und Auswertung , 1988 .

[166]  H. Lodish,et al.  Elevated levels of glucose transport and transporter messenger RNA are induced by ras or src oncogenes. , 1987, Science.

[167]  G. Weber.  Enzymology of cancer cells (second of two parts). , 1977, The New England journal of medicine.

[168]  Otto Warburn,et al.  THE METABOLISM OF TUMORS , 1931 .